Management of Rheumatoid Arthritis

[1] Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016 Oct 22;388(10055):2023-2038. doi: 10.1016/S0140-6736(16)30173-8. Epub 2016 May 3. Erratum in: Lancet. 2016 Oct 22;388(10055):1984. doi: 10.1016/S0140-6736(16)30794-2. PMID: 27156434.

[2] van der Linden MP, le Cessie S, Raza K, et al. Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum. 2010 Dec;62(12):3537-46. doi: 10.1002/art.27692. PMID: 20722031.

[3] Orange DE, Blachere NE, DiCarlo EF,et al. Rheumatoid Arthritis Morning Stiffness Is Associated With Synovial Fibrin and Neutrophils. Arthritis Rheumatol. 2020 Apr;72(4):557-564. doi: 10.1002/art.41141. Epub 2020 Feb 12. PMID: 31612614; PMCID: PMC7113097.

[4] Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010 Sep;62(9):2569-81. doi: 10.1002/art.27584. PMID: 20872595.

[5] Sokolova MV, Schett G, Steffen U. Autoantibodies in Rheumatoid Arthritis: Historical Background and Novel Findings. Clin Rev Allergy Immunol. 2022 Oct;63(2):138-151. doi: 10.1007/s12016-021-08890-1. Epub 2021 Sep 8. PMID: 34495490; PMCID: PMC9464122.

[6] Niewold TB, Harrison MJ, Paget SA. Anti-CCP antibody testing as a diagnostic and prognostic tool in rheumatoid arthritis. QJM. 2007 Apr;100(4):193-201. doi: 10.1093/qjmed/hcm015. PMID: 17434910.

[7] Mohammed RH, Bhutta BS. Hand and Wrist Rheumatoid Arthritis. [Updated 2023 Aug 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560890/

[8] Rheumatoid arthritis in adults: diagnosis and management. London: National Institute for Health and Care Excellence (NICE); 2018 Jul 11. PMID: 30102507.

[9] Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford). 2004 Jul;43(7):906-14. doi: 10.1093/rheumatology/keh199. Epub 2004 Apr 27. PMID: 15113999.

[10] Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404–13.doi:10.1136/ard.2011.149765

[11] Aletaha D , Alasti F , Smolen JS . Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point. Ann Rheum Dis 2016;75:1479–85.doi:10.1136/annrheumdis-2015-208324 

[12] Aletaha D, Funovits J, Keystone EC, et al. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 2007;56:3226–35.

[13] Pincus T, Yazici Y, Sokka T, et al. Methotrexate as the “anchor drug” for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 2003;21(Suppl 31):S178–85.

[14] Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 2009;68:1094–9. 

[15] Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021 Jul;73(7):924-939. doi: 10.1002/acr.24596. Epub 2021 Jun 8. PMID: 34101387; PMCID: PMC9273041.

[16] Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 1999;353:259–66.

[17] Katz SJ, Russell AS. Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action. Curr Opin Rheumatol 2011;23:278–81.

[18] O'Dell JR, Mikuls TR, Taylor TH, et al; CSP 551 RACAT Investigators. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. 2013 Jul 25;369(4):307-18. doi: 10.1056/NEJMoa1303006. Epub 2013 Jun 11. PMID: 23755969.

[19] Svensson B, Boonen A, Albertsson K, et al. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum 2005;52:3360–70.

[20] da Silva JA, Jacobs JW, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 2006;65:285–93.

[21] Holloway K, van Dijk L. The world medicines situation 2011. rational use of medicines. Geneva: World Health Organzization, 2011.doi:WHO/EMP/MIE/2011.2.2

[22] European Medicines Agency. Xeljanz (tofacitinib): increased risk of major adverse cardiovascular events and malignancies with use of tofacitinib relative to TNF-alpha inhibitors, 2021.

[23] Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023 Jan;82(1):3-18. doi: 10.1136/ard-2022-223356. Epub 2022 Nov 10. Erratum in: Ann Rheum Dis. 2023 Mar;82(3):e76. doi: 10.1136/ard-2022-223356corr1. PMID: 36357155.

 [24] Burmester G-R, Kivitz AJ, Kupper H, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised concerto trial. Ann Rheum Dis 2015;74:1037–44.doi:10.1136/annrheumdis-2013-204769

[25] Gabay C, Emery P, van VR, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013;381:1541–50.

[26] Fleischmann R, Takeuchi T, Schlichting D, et al. Baricitinib, methotrexate, or baricitinib plus methotrexate in patients with early rheumatoid arthritis who had received limited or no treatment with disease-modifying anti-rheumatic drugs (DMARDs): phase 3 trial results [abstract]. Arhritis Rheum 2015;67 (Suppl 10).

[27] Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020;79:685–99.doi:10.1136/annrheumdis-2019-216655pmid: http://www.ncbi.nlm.nih.gov/pubmed/31969328

[28] Gossec L, Bijlsma JW, Bombardier C, et al. Dissemination and evaluation of the 3E initiative recommendations for use of methotrexate in rheumatic disorders: results of a study among 2233 rheumatologists. Ann Rheum Dis. 2011 Feb;70(2):388-9. doi: 10.1136/ard.2010.128652. Epub 2010 May 14. PMID: 20472594.

[29] American Association for the Study of Liver Diseases. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Clin Liver Dis (Hoboken) 2018; 11: 81

[30] Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018; 67: 1560–99.

[31] Baker JF, Sauer B, Teng CC,et al. Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis Is Associated With Changes in Blood Pressure. J Clin Rheumatol. 2018 Jun;24(4):203-209. doi: 10.1097/RHU.0000000000000736. PMID: 29664818; PMCID: PMC7461421.

[32] Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107: 3133–40.

[33] Narváez J, Díaz Del Campo Fontecha P, Brito García N,et al. SER-SEPAR recommendations for the management of rheumatoid arthritis-related interstitial lung disease. Part 2: Treatment. Reumatol Clin (Engl Ed). 2022 Nov;18(9):501-512. doi:10.1016/j.reumae.2022.03.004. Epub 2022 Sep 3. PMID: 36064885.

[34] Russell MD, Dey M, Flint J,et al.; BSR Standards, Audit and Guidelines Working Group. Executive Summary: British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford). 2023 Apr 3;62(4):1370-1387. doi:10.1093/rheumatology/keac558. PMID: 36318965; PMCID: PMC10070067.

[35] Vallejo-Yagüe E, Keystone EC, Kandhasamy S, Micheroli R, Finckh A, Burden AM. Primary and secondary non-response: in need of operational definitions in observational studies. Ann Rheum Dis. 2021 Aug;80(8):961-964. doi: 10.1136/annrheumdis-2021-220202. Epub 2021 Apr 21. PMID: 33883161; PMCID: PMC8292559.

[36] Nagy G, Roodenrijs NMT, Welsing PM, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021 Jan;80(1):31-35. doi: 10.1136/annrheumdis-2020-217344. Epub 2020 Oct 1. PMID: 33004335; PMCID: PMC7788062.